Clinical trials: Obesity & Overweight
Obesity With Diabetes, Overweight With Diabetes
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: Percent change in body weight Change in hemoglobin A1c (HbA1c)
- Trial name
- KaiNETIC-2 (NCT07284901)
- Testing
- Ribupatide
- Where
- 173 sites in United States, Argentina and 9 more
- Volunteers
- 1,270 people
- Sponsor
- Kailera
Overweight, Obesity
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity.
- Trial name
- NCT06916065
- Testing
- Eloralintide and Tirzepatide, Eloralintide
- Where
- 3 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eli Lilly and Company
Prader-Willi Syndrome
Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
The primary objective of this study is to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior in patients with Prader-Willi Syndrome (PWS).
- Trial name
- NCT02844933
- Testing
- Cannabidiol
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss.
- Trial name
- SURMOUNT-4 (NCT04660643)
- Testing
- Tirzepatide
- Where
- 70 sites in United States, Argentina and 3 more
- Volunteers
- 783 people
- Sponsor
- Eli Lilly and Company
Weight Management, Treatment Of Obesity
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes
- Trial name
- NCT00542009
- Testing
- CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD
- Where
- 54 sites in United States, Bulgaria and 5 more
- Volunteers
- 252 people
- Sponsor
- Pfizer
Obesity, Binge-Eating Disorder
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
The purpose of this study is to evaluate the safety and effectiveness of topiramate compared to placebo in reducing the number of binge days in patients with moderate to severe binge-eating disorder associated with obesity.
- Trial name
- NCT00210808
- Testing
- topiramate
- Volunteers
- 407 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight/ Obesity
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
This is a multicenter, double-blind, randomized, placebo-controlled study conducted in overweight or obese subjects. This study is divided into the first stage and the second stage.
- Trial name
- NCT04904913
- Testing
- IBI362
- Where
- China
- Volunteers
- 328 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
Crave Crush Behavioral Study
The purpose of the research is to determine if participants who take "Crave Crush" will report lower cravings and palatability ratings of candy as compared to subjects who receive the placebo.
- Trial name
- NCT02744885
- Testing
- Crave Crush
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Overweight, Obesity
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight.
- Trial name
- RENEW 4 (NCT07745504)
- Testing
- Cagrilintide
- Where
- 36 sites in United States, Greece and 4 more
- Volunteers
- 285 people
- Sponsor
- Novo Nordisk A/S
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes
The purpose of this study is to investigate (1) the effect of topiramate on insulin sensitivity in overweight or obese patients with type 2 diabetes mellitus and (2) the safety of topiramate in type 2 diabetic patients.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00236626
- Testing
- topiramate
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity, Dyslipidemia
Obese Patients With Untreated Dyslipidemias
To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia
- Trial name
- RIO-Lipids (NCT00029835)
- Testing
- Rimonabant (SR141716)
- Where
- 35 sites in United States, Australia and 6 more
- Volunteers
- 1,033 people
- Sponsor
- Sanofi
Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure
Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity
The goal of this study is to examine the relationship in individuals with overweight/obesity and endocrine disrupting chemical (EDC) exposure through a two-armed, randomized clinical trial.
- Conditions
- Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure, Overweight (BMI > 25)
- Trial name
- LiveWell (NCT07560579)
- Testing
- Educational curriculum, Weight loss Application, Urinary EDC metabolite testing
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Million Marker Wellness, Inc.
Type 2 Diabetes Mellitus
A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
Objectives: Primary Objectives To investigate the safety and tolerability of single ascending doses of AZP- 531 in healthy volunteers.
- Trial name
- NCT02040012
- Testing
- AZP-531
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Alizé Pharma
Sleep Apnea, Obstructive, Obesity
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight.
- Conditions
- Sleep Apnea, Obstructive, Obesity, Overweight
- Trial name
- ENLIGHTEN-3 (NCT07369011)
- Testing
- Eloralintide
- Where
- 115 sites in United States, Australia and 9 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
Obesity, Morbid
The ReNEW Study: Maestro® New Enrollment Post-Approval Study Protocol
This is a five-year, single arm, multi-center trial to evaluate the long-term safety and efficacy of the Maestro Rechargeable System in treating obesity. The study will include an observational arm and a randomized sub-study.
- Trial name
- ReNEW (NCT03145636)
- Testing
- vBloc Maestro Rechargeable System, vBloc Achieve Weight Management Program, Control Weight Management (CWM) program
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- ReShape Lifesciences
Monogenic Obesity
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
This study is researching an experimental drug called mibavademab. The study is focused on patients with a condition called monogenic obesity.
- Trial name
- NCT07220772
- Testing
- Mibavademab
- Where
- 3 sites in Germany, Turkey (Türkiye)
- Volunteers
- 4 people
- Sponsor
- Regeneron Pharmaceuticals
Prediabetes, Overweight
Evaluation of Prevent in Underserved Populations
The goal of this study is to evaluate an online Diabetes Prevention Program adapted for patients with prediabetes in safety net health care settings.
- Conditions
- Prediabetes, Overweight, Obesity
- Trial name
- PUP (NCT02664064)
- Testing
- Prevent
- Where
- 3 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Omada Health, Inc.
Obesity, Women
Probiotics' Effects on Hormones, Body and Mood in Obese Women
To evaluate the regulatory effect of probiotics formula on visceral fat metabolism and sex hormone balance in obese women.
- Trial name
- NCT07013409
- Testing
- Probiotic, Maltodextrin
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Overweight and Obesity
Efficacy of Polyglucosamine for Weight Loss
The polyglucosamine, specification L112 is a medical device and in this clinical trial used for weight reduction of overweight and obese participants.
- Trial name
- NCT02410785
- Testing
- Polyglucosamine
- Where
- 2 sites in Germany, Italy
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.